CA2203379A1 - Cgmp-pde inhibitors for the treatment of erectile dysfunction - Google Patents

Cgmp-pde inhibitors for the treatment of erectile dysfunction

Info

Publication number
CA2203379A1
CA2203379A1 CA 2203379 CA2203379A CA2203379A1 CA 2203379 A1 CA2203379 A1 CA 2203379A1 CA 2203379 CA2203379 CA 2203379 CA 2203379 A CA2203379 A CA 2203379A CA 2203379 A1 CA2203379 A1 CA 2203379A1
Authority
CA
Canada
Prior art keywords
treatment
cgmp
erectile dysfunction
pde inhibitors
pde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2203379
Other languages
French (fr)
Other versions
CA2203379C (en
Inventor
Simon Fraser Campbell
Alexander Roderick Mackenzie
Anthony Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Simon Fraser Campbell
Alexander Roderick Mackenzie
Anthony Wood
Pfizer Research And Development Company, N.V./S.A.
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9423910A external-priority patent/GB9423910D0/en
Application filed by Simon Fraser Campbell, Alexander Roderick Mackenzie, Anthony Wood, Pfizer Research And Development Company, N.V./S.A., Pfizer Limited filed Critical Simon Fraser Campbell
Publication of CA2203379A1 publication Critical patent/CA2203379A1/en
Application granted granted Critical
Publication of CA2203379C publication Critical patent/CA2203379C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
CA 2203379 1994-11-26 1995-10-16 Cgmp-pde inhibitors for the treatment of erectile dysfunction Expired - Fee Related CA2203379C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9423910A GB9423910D0 (en) 1994-11-26 1994-11-26 Therapeutic agents
GB9423910.0 1994-11-26
PCT/EP1995/004066 WO1996016644A1 (en) 1994-11-26 1995-10-16 cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION

Publications (2)

Publication Number Publication Date
CA2203379A1 true CA2203379A1 (en) 1996-06-06
CA2203379C CA2203379C (en) 2006-01-03

Family

ID=29403918

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2203379 Expired - Fee Related CA2203379C (en) 1994-11-26 1995-10-16 Cgmp-pde inhibitors for the treatment of erectile dysfunction

Country Status (1)

Country Link
CA (1) CA2203379C (en)

Also Published As

Publication number Publication date
CA2203379C (en) 2006-01-03

Similar Documents

Publication Publication Date Title
MX9703868A (en) cGMP-PDE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
IL138907A0 (en) Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
HK1027808A1 (en) Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cgmp pde5) for the treatment of sexual dysfunction.
CA2348086A1 (en) Controlled-release pharmaceutical formulations
CA2275554A1 (en) Intranasal formulations for treating sexual disorders
HK1039328A1 (en) Pyrazolopyrimidinone derivatives for the treatment of impotence
BG102879A (en) Carbolin derivatives
CA2309332A1 (en) 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
EP1005336A4 (en) Improved methods and compositions for treating male erectile dysfunction
EP1027054A4 (en) Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU4199489A (en) Composition for the treatment of erectile dysfunction
CA2248266A1 (en) Immunosuppressive compounds and methods
AU2001244192A1 (en) Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction
WO1999030697A3 (en) Combination effective for the treatment of impotence
DZ3171A1 (en)
CA2342830A1 (en) 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
CA2262268A1 (en) Method of treating impotence due to spinal cord injury
HUP0003219A3 (en) Phthalazine derivatives, process for producing them and pharmaceutical compositions containing them and use of the compounds for producing pharmaceutical compositions useful for treating erectile dysfunction
NZ530587A (en) Diazacycloalkanes as oxytocin agonists
AU3048501A (en) An improved pharmaceutical composition for treating male erectile dysfunction
AU3776799A (en) Methods for treating female sexual dysfunction
CA2203379A1 (en) Cgmp-pde inhibitors for the treatment of erectile dysfunction
ZA200203069B (en) Peptides for treatment of erectile dysfunction.
ZA200000578B (en) Process for the preparation of organic azides.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed